Comparison of weekly and triweekly cisplatin regimens during concurrent chemoradiotherapy for nasopharyngeal carcinoma

Table 1 Baseline characteristics of the 322 patients who received concurrent chemoradiotherapy

Characteristic	Weekly Group		Triweekly Group		Total		P
Characteristic	No.	%	No.	%	No.	%	P
Age							0.985^b
≤44	47	50.5	116	50.7	163	50.6
>44	46	49.5	113	49.3	159	49.4
Sex							0.076^b
Male	83	89.2	217	94.8	300	93.2
Female	10	10.8	12	5.2	22	6.8
Smoking							0.915^b
No	74	79.6	181	79.0	255	79.2
Yes	19	20.4	48	21.0	67	20.8
Drink							0.201^b
No	91	97.8	228	99.6	319	99.1
Yes	2	2.2	1	0.4	3	0.9
Histology^a							0.560^b
Non-keratinizing Undifferentiated (type III)	93	100	226	98.7	319	99.1
Others (type I and II)	0	0	3	1.3	3	0.9
T stage (8^th AJCC)							0.941^b
T1–2	39	41.9	95	41.5	134	41.6
T3–4	54	58.1	134	58.5	188	58.4
N stage (8^th AJCC)							0.172^b
N0–1	80	86.0	182	79.5	262	81.4
N2–3	13	14.0	47	20.5	60	18.6
Stage (8^th AJCC)							0.475^b
I–II	36	38.7	79	34.5	115	35.7
III–IVA	57	61.3	150	65.5	207	64.3
EBV							0.621^b
≤4000 copy/ml	62	66.7	146	63.8	208	64.6
>4000 copy/ml	31	33.3	83	36.2	114	35.4
Cumulative cisplatin	190.54	53.27^d	202.97	54.39^d			0.062^c

Abbreviations: T NPC tumor stage, N nodal stage, CCRT concurrent chemoradiotherapy, AJCC American Joint Committee on Cancer, EBV Epstein–Barr virus
^aHistology was categorized according to the WHO Classification of Tumors
^bChi-square test or Fisher’s exact test
^cStudent’s t-test
^dStandard deviation

ISSN: 1471-2407